The Impact of Radiotherapy Dose in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy

被引:11
作者
Lo, Chien-Ming [1 ]
Wang, Yu-Ming [2 ]
Chen, Yen-Hao [3 ]
Fang, Fu-Min [2 ]
Huang, Shun-Chen [4 ]
Lu, Hung-, I [1 ]
Li, Shau-Hsuan [3 ]
机构
[1] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Thorac & Cardiovasc Surg, Kaohsiung 833401, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, Kaohsiung 833401, Taiwan
[3] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Hematol Oncol, Kaohsiung 833401, Taiwan
[4] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Pathol, Kaohsiung 833401, Taiwan
关键词
esophageal squamous cell carcinoma; chemoradiotherapy; esophagectomy; radiotherapy dose; PHASE-III TRIAL; NEOADJUVANT CHEMORADIATION; SURGERY; CANCER; CHEMOTHERAPY; SURVIVAL; THERAPY;
D O I
10.3390/curroncol28020129
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: For patients with esophageal squamous cell carcinoma, preoperative chemoradiotherapy followed by planned esophagectomy is used as a curative treatment modality. However, the impact of radiotherapy dose remains undefined. Method: A total of 141 patients with stage III esophageal squamous cell carcinoma (ESCC; as defined by the 7th American Joint Committee on Cancer), receiving preoperative chemoradiotherapy followed by esophagectomy between 2000 and 2015 at Kaohsiung Chang Gung Memorial Hospital, Taiwan, were retrospectively reviewed. The radiotherapy dose of preoperative chemoradiotherapy (36 Gy before 2009 and 50-50.4 Gy after 2009) and other clinicopathological parameters were collected and correlated with the response to chemoradiotherapy and treatment outcome. Result: Of these 141 patients, the radiotherapy dose was 36 Gy in 59 (42%) patients and 50 Gy in 82 (58%) patients. A complete pathological response was noted in 12 (20%) of 59 patients receiving 36 Gy radiotherapy, and 37 (45%) of 82 patients receiving 50 Gy radiotherapy (p = 0.002). The three-year overall survival and disease-free survival rates were 31% and 25% in patients receiving 36 Gy radiotherapy, and 54% and 46% in patients receiving 50-50.4 Gy radiotherapy, respectively (p = 0.023 for overall survival; p = 0.047 for disease-free survival). Multivariate analysis showed that a higher radiotherapy dose was associated with increased pathological complete response (p = 0.003, hazard ratio: 3.215), better overall survival (p = 0.024, hazard ratio: 1.585), and superior disease-free survival (p = 0.049, hazard ratio: 1.493). However, higher radiotherapy doses revealed more surgical complications, including acute respiratory distress syndrome (p = 0.048) and anastomosis leaks (p = 0.004). Conclusion: For patients with locally advanced ESCC, preoperative chemoradiotherapy with higher radiotherapy doses led to increased pathologic complete response rates and improved survival.
引用
收藏
页码:1354 / 1365
页数:12
相关论文
共 26 条
[11]   JMJD3 expression is an independent prognosticator in patients with esophageal squamous cell carcinoma [J].
Li, Shau-Hsuan ;
Lu, Hung-I ;
Chen, Yen-Hao ;
Lo, Chien-Ming ;
Huang, Wan-Ting ;
Tien, Wan-Yu ;
Lan, Ya-Chun ;
Tsai, Hsin-Ting ;
Chen, Chang-Han .
SURGERY, 2019, 165 (05) :946-952
[12]   Comparison of Up-Front Minimally Invasive Esophagectomy versus Open Esophagectomy on Quality of Life for Esophageal Squamous Cell Cancer [J].
Li, Zhenhua ;
Cheng, Jingge ;
Zhang, Yuefeng ;
Wen, Shiwang ;
Lv, Huilai ;
Xu, Yanzhao ;
Zhu, Yonggang ;
Zhang, Zhen ;
Mu, Donghui ;
Tian, Ziqiang .
CURRENT ONCOLOGY, 2021, 28 (01) :693-701
[13]   Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution [J].
Natsugoe, S. ;
Okumura, H. ;
Matsumoto, M. ;
Uchikado, Y. ;
Setoyama, T. ;
Yokomakura, N. ;
Ishigami, S. ;
Owaki, T. ;
Aikou, T. .
DISEASES OF THE ESOPHAGUS, 2006, 19 (06) :468-472
[14]   PREOPERATIVE RADIOTHERAPY PROLONGS SURVIVAL IN OPERABLE ESOPHAGEAL-CARCINOMA - A RANDOMIZED, MULTICENTER STUDY OF PREOPERATIVE RADIOTHERAPY AND CHEMOTHERAPY - THE 2ND SCANDINAVIAN TRIAL IN ESOPHAGEAL CANCER [J].
NYGAARD, K ;
HAGEN, S ;
HANSEN, HS ;
HATLEVOLL, R ;
HULTBORN, R ;
JAKOBSEN, A ;
MANTYLA, M ;
MODIG, H ;
MUNCKWIKLAND, E ;
ROSENGREN, B ;
TAUSJO, J ;
ELGEN, K .
WORLD JOURNAL OF SURGERY, 1992, 16 (06) :1104-1110
[15]   Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer [J].
Prenzel, Klaus L. ;
Koenig, Alexandra ;
Schneider, Paul M. ;
Schnickmann, Christian ;
Baldus, Stephan E. ;
Schroeder, Wolfgang ;
Bollschweiler, Elfriede ;
Dienes, Hans P. ;
Mueller, Rolf P. ;
Izbicki, Jakob R. ;
Hoelscher, Arnulf H. .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) :954-959
[16]   The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers [J].
Shain, A. Hunter ;
Pollack, Jonathan R. .
PLOS ONE, 2013, 8 (01)
[17]   Locally advanced esophageal cancer. [J].
Sherman C.A. ;
Turrisi A.T. ;
Wallace M.B. ;
Reed C.E. .
Current Treatment Options in Oncology, 2002, 3 (6) :475-485
[18]   Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus [J].
Stahl, M ;
Stuschke, M ;
Lehmann, N ;
Meyer, HJ ;
Walz, MK ;
Seeber, S ;
Klump, B ;
Budach, W ;
Teichmann, R ;
Schmitt, M ;
Schmitt, G ;
Franke, C ;
Wilke, H .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2310-2317
[19]   Etiology and chemoprevention of esophageal squamous cell carcinoma [J].
Stoner, GD ;
Gupta, A .
CARCINOGENESIS, 2001, 22 (11) :1737-1746
[20]   Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 [J].
Tepper, Joel ;
Krasna, Mark J. ;
Niedzwiecki, Donna ;
Hollis, Donna ;
Reed, Carolyn E. ;
Goldberg, Richard ;
Kiel, Krystyna ;
Willett, Christopher ;
Sugarbaker, David ;
Mayer, Robert .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) :1086-1092